Marina Biotech, Inc. Forecasted to Earn FY2020 Earnings of ($1.76) Per Share (MRNA)

Marina Biotech, Inc. (OTCMKTS:MRNA) – Research analysts at Oppenheimer dropped their FY2020 EPS estimates for shares of Marina Biotech in a report issued on Monday, May 13th. Oppenheimer analyst H. Singh now expects that the biotechnology company will post earnings per share of ($1.76) for the year, down from their prior estimate of ($1.75). Oppenheimer currently has a “Buy” rating on the stock.

MRNA has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Marina Biotech from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. Chardan Capital initiated coverage on shares of Marina Biotech in a report on Friday, April 5th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Piper Jaffray Companies boosted their price objective on shares of Marina Biotech from $24.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $27.10.

Shares of Marina Biotech stock opened at $23.59 on Thursday. Marina Biotech has a twelve month low of $13.03 and a twelve month high of $29.79.

Marina Biotech (OTCMKTS:MRNA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The company had revenue of $16.03 million for the quarter, compared to analysts’ expectations of $33.59 million.

Institutional investors have recently modified their holdings of the company. Essex Investment Management Co. LLC bought a new stake in shares of Marina Biotech during the 4th quarter valued at about $146,000. Parallel Advisors LLC bought a new position in Marina Biotech in the 1st quarter worth about $207,000. Bainco International Investors bought a new position in Marina Biotech in the 1st quarter worth about $224,000. Moloney Securities Asset Management LLC bought a new position in Marina Biotech in the 1st quarter worth about $1,051,000. Finally, Canada Pension Plan Investment Board bought a new position in Marina Biotech in the 4th quarter worth about $24,430,000.

About Marina Biotech

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

See Also: Discount Rate

Earnings History and Estimates for Marina Biotech (OTCMKTS:MRNA)

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit